Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST. - Wikidata - thesis-toulmin - TriplyDB

Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST.

Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST.

http://www.wikidata.org/entity/Q37988591

about

Reintroduction of imatinib in GIST Macroporous hydrogel micropillars for quantifying Met kinase activity in cancer cell lysates.

P2860

Q37301364-2EED4086-AAA4-4F1F-8451-204DCF256A90 Q39311676-CF0C79BC-1344-4B6E-BAA9-B381BAAC1AA5

P2860

Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST.

http://www.wikidata.org/entity/Q37988591

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST.

@en

Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST.

@nl

type

label

Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST.

@en

Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST.

@nl

prefLabel

Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST.

@en

Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST.

@nl

P1433

Q37988591-637867CA-CDCE-4D01-8845-2886A1112A9B

P1476

Q37988591-40ADB786-506E-435E-AAA1-938C37FB9E97

P2093

Q37988591-BC867362-78F1-4976-BFF2-10ECDFC4B86E

P2860

Q37988591-0E2864DD-AFFA-4DD4-871B-36FEBC0067F0

Q37988591-0F609C24-75B6-45F2-82D0-5254AD469E70

Q37988591-25467073-D153-4707-9DBC-5D6187681818

Q37988591-2B4D3883-D37F-4DDC-A798-C832FE19D2D5

Q37988591-2C509E44-1801-4FB3-96E8-40A58445CC2C

Q37988591-321668DD-4E85-4BFD-8C86-24DB3FC53583

Q37988591-33343593-960D-4A64-8ACF-DAF16407CF7D

Q37988591-49066ADC-4E9E-4973-B6E7-610077F73905

Q37988591-4909BAF7-3B79-4689-B34C-FE35B634762A

Q37988591-4BA38A45-BAE0-4AAA-B553-A16C332393FC

P304

Q37988591-69E00200-2163-4B98-9CED-5A87AF22D446

P31

Q37988591-45037F12-D8DC-4BB0-BC1D-F5A63E40B2AB

P356

Q37988591-4497642A-08ED-4209-ABA4-18DDFFBAC8B3

P433

Q37988591-D5BA83C1-ED75-475F-8B75-64A1261C4DD4

P478

Q37988591-2427D31D-F98B-40EC-B18A-7F4DF45F6129

P50

Q37988591-0CBB2FBD-0644-40C5-8A93-DD7D58593D3D

P577

Q37988591-3B0DB9E1-8744-490E-9263-6CD56E6A20C5

P5875

Q37988591-5FF9345F-518E-4654-9D34-493E069CF964

P698

Q37988591-99830CB2-8829-4F3F-A194-424DCA137879

P356

J.1743-7563.2011.01491.X

P1433

Asia Pacific Journal of Clinical Oncology

P1476

Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST

@en

P2093

John R Zalcberg

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment.

Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.

P304

43-52

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1743-7563.2011.01491.X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221865669

http://www.w3.org/2001/XMLSchema#string

P698

22369443

http://www.w3.org/2001/XMLSchema#string